SecBot SecBot
8-K ·Filed Apr 21, 2026

RIGL

RIGEL PHARMACEUTICALS INC
BEARISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001034842-26-000027
8-K material event: Items 1.02
Actionable Insight ▼ Bearish

The termination removes a major source of potential future revenue and de-risks Rigel's pipeline, which was dependent on Lilly's development efforts. Traders should assess whether Rigel can independently advance the RIPK1 programs and consider the impact on the company's valuation, particularly given its $600M market cap.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$30.47
T+0 close · Apr 21, 2026 · via day close
Latest settled
+33.05%
T+60 · $40.54
Vs SPY
+28.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 22 $30.47entry
  2. T+1 · 7mo ago +0.82%α +1.21% · $30.72
  3. T+5 · 7mo ago −4.30%α −4.35% · $29.16
  4. T+20 · 6mo ago −7.12%α −10.29% · $28.30
  5. T+60 · 4mo ago +33.05%α +28.27% · $40.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rigel Pharmaceuticals announced that Eli Lilly has elected to terminate their 2021 License and Collaboration Agreement, effective June 15, 2026. The agreement covered the development and commercialization of ocadusertib and other RIPK1 inhibitors. Rigel will regain full rights but does not expect future milestones or royalties.

Key Facts

  • Eli Lilly terminated the License and Collaboration Agreement dated February 18, 2021
  • Termination becomes effective on June 15, 2026
  • Agreement covered ocadusertib (R552) and other RIPK1 inhibitors for CNS and non-CNS diseases
  • Rigel will regain full rights to the licensed compounds
  • Company does not expect to receive future milestones or royalties under the agreement

Financial Impact

Loss of potential future milestone payments and royalties from Lilly; no further revenue expected from the collaboration

revenuefuture cash flowpipeline valuation

Risk Factors

  • Loss of development funding and commercialization expertise from Lilly
  • Uncertainty around Rigel's ability to independently develop and fund the RIPK1 programs
  • Downward pressure on valuation due to lost future royalty stream

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001034842-26-000027
Document: 0001034842-26-000027-index.html0001034842-26-000027
Document: 0001034842-26-000027.txt0001034842-26-000027

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026